An Open Label, Non-Randomized, Single Dose, Two Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Jun 2017
At a glance
- Drugs Lanopepden (Primary) ; Lanopepden (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Aug 2012 New trial record